Search results for "INDEX"

showing 10 items of 5395 documents

Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre st…

2016

Ajuda rebuda: GlaxoSmithKline Several glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1Ra) have been made recently available in Spain for type 2 diabetes mellitus (DM2) treatment. There are no published data on the clinical and sociodemographic profile of patients initiating treatment with GLP-1Ra in Spain. Our objective was to understand these patients' characteristics in a real-world clinical practice setting. Design. Cross-sectional observational study. Setting. Spanish specialist outpatient clinics.Participants 403 adults with DM2 initiating GLP-1Ra treatment were included. Primary and secondary outcome measures Sociodemographic and DM2-related clinical data, including treatment …

medicine.medical_specialtyDM2Cross-sectional studymedicine.medical_treatment030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineInsulinaInternal medicinemedicineOutpatient clinic030212 general & internal medicineMedical prescriptionGlucagon-like peptide 1 receptorDiabetisbusiness.industryInsulinDiabetis mellitus tipus 2Type 2 Diabetes MellitusGeneral MedicineDiabetes mellitus tipo 2EndocrinologyConcomitantMalalties d'origen nutricionalbusinessBody mass index
researchProduct

The Value of BISAP Score for Predicting Mortality and Severity in Acute Pancreatitis: A Systematic Review and Meta-Analysis

2015

Purpose The Bedside Index for Severity in Acute Pancreatitis (BISAP) score has been developed to identify patients at high risk for mortality or severe disease early during the course of acute pancreatitis. We aimed to undertake a meta-analysis to quantify the accuracy of BISAP score for predicting mortality and severe acute pancreatitis (SAP). Materials and Methods We searched the databases of Pubmed, Embase, and the Cochrane Library to identify studies using the BISAP score to predict mortality or SAP. The pooled sensitivity, specificity, likelihood ratios, and diagnostic odds ratio (DOR) were calculated from each study and were compared with the traditional scoring systems. Results Twelv…

medicine.medical_specialtyDatabases Factuallcsh:MedicineSeverity of Illness Indexlaw.inventionlawSeverity of illnessOdds RatiomedicineHumanslcsh:ScienceIntensive care medicineMultidisciplinarybusiness.industryMortality ratelcsh:RCorrectionOdds ratiomedicine.diseaseSurvival AnalysisIntensive care unitSystematic reviewPancreatitisMeta-analysisAcute DiseasePancreatitisAcute pancreatitislcsh:QbusinessResearch ArticlePLOS ONE
researchProduct

A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes

2015

Contains fulltext : 152084.pdf (Publisher’s version ) (Open Access) BACKGROUND: Optimal glucose-lowering therapy in type 2 diabetes mellitus requires a patient-specific approach. Although a good framework, current guidelines are insufficiently detailed to address the different phenotypes and individual needs of patients seen in daily practice. We developed a patient-specific decision support tool based on a systematic analysis of expert opinion. MATERIALS AND METHODS: Based on the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) 2012 position statement, a panel of 12 European experts rated the appropriateness (RAND/UCLA Appropriateness Method) of tre…

medicine.medical_specialtyDecision support systemEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]MEDLINEType 2 diabetesComorbidityHypoglycemiaGlucagon-Like Peptide-1 ReceptorBody Mass IndexEndocrinologyLife ExpectancyClinical ProtocolsInternal medicineHealth careReceptors GlucagonMedicineHumansHypoglycemic AgentsInsulinPrecision MedicineIntensive care medicineExpert TestimonyReimbursementComputingMilieux_MISCELLANEOUSGlycated HemoglobinDipeptidyl-Peptidase IV InhibitorsPioglitazonebusiness.industryDrug SubstitutionType 2 Diabetes MellitusMetabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6]Original ArticlesPrecision medicinemedicine.diseaseDecision Support Systems ClinicalHypoglycemiaMetformin3. Good healthEuropeMedical Laboratory TechnologyEndocrinologySulfonylurea CompoundsDiabetes Mellitus Type 2Drug Therapy CombinationThiazolidinedionesbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

The relationship between PASI and DLQI with itch, stress, and depression: Do we need additional decision‐making tools in psoriasis?

2019

medicine.medical_specialtyDepressionbusiness.industryMEDLINEDermatologyGeneral Medicinemedicine.diseaseSeverity of Illness IndexQuality of lifePsoriasisSeverity of illnessQuality of LifemedicineHumansPsoriasisPsychiatrybusinessDepression (differential diagnoses)Dermatologic Therapy
researchProduct

TNF-α blockade may lead to improvement of vascular function in psoriasis patients.

2021

Psoriasis is one of the most common chronic inflammatory skin diseases and at the same time a risk factor for cardiovascular disease. Interleukin-17A (IL-17A)-mediated inflammation in psoriasis may lead to vascular dysfunction. This study aimed at investigating whether anti-inflammatory treatment by tumor necrosis factor (TNF)-α blockade alters vascular function in psoriasis patients. A total of 11 patients with psoriasis who underwent treatment with either adalimumab (n = 8) or etanercept (n = 3), 10 healthy control individuals and 14 patients with coronary artery disease (CAD) were included in this study. Treatment response was assessed using the Psoriasis Area and Severity Index (PASI) s…

medicine.medical_specialtyDermatologyBiochemistryGastroenterologyEtanerceptCoronary artery diseasePsoriasis Area and Severity IndexInternal medicinePsoriasismedicineAdalimumabHumansPsoriasisRisk factorMolecular Biologybusiness.industryTumor Necrosis Factor-alphamedicine.diseaseBlockadeVasodilationVasoconstrictionChronic DiseaseTumor necrosis factor alphaTumor Necrosis Factor InhibitorsEndothelium Vascularbusinessmedicine.drugExperimental dermatologyREFERENCES
researchProduct

May Measurement Month 2019 : an analysis of blood pressure screening results from Poland

2021

Abstract May Measurement Month 2019 is the third edition of a global initiative organized by the International Society of Hypertension aimed at raising awareness of hypertension and the need for blood pressure (BP) screening. We present data analysis from Poland. To evaluate the potential of opportunistic BP measurements as a tool for cardiovascular disease prevention programmes. To collect new country data for further annual comparisons. An opportunistic cross-sectional survey of volunteers aged ≥18 was carried out in 201 sites in May 2019. BP was measured in 7072 subjects (mean age: 54 ± 15 years; 62.3% females). After multiple imputation, the age- and sex-standardized systolic BP (SBP) a…

medicine.medical_specialtyDiastole030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusEpidemiologyControlmedicineAcademicSubjects/MED00200030212 general & internal medicine1102 Cardiorespiratory Medicine and HaematologySecondary preventionbusiness.industryMean ageArticlesmedicine.diseaseTreatmentBlood pressureCardiovascular System & HematologyHypertensionBlood pressureScreeningDisease awarenessDisease preventionCardiology and Cardiovascular MedicinebusinessBody mass index
researchProduct

May Measurement Month 2018 : an analysis of blood pressure screening campaign results from Poland

2020

Abstract Hypertension remains the most important cardiovascular risk factor in Poland. May Measurement Month is a global initiative organized by the International Society of Hypertension aimed at raising awareness of hypertension and the need for blood pressure (BP) screening and demonstrating the potential of the opportunistic BP measurements. An opportunistic cross-sectional survey of volunteers aged ≥18 was carried out in 146 sites in May 2018. Blood pressure was measured in 6450 subjects (mean age: 41 ± 15 years; 59% females). After multiple imputation, the age and sex standardized systolic and diastolic BP was 126.7/78.4 mmHg in the whole analysed group, 132.8/81.3 mmHg in subjects tak…

medicine.medical_specialtyDiastoleDisease030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusControlmedicineAcademicSubjects/MED00200Risk factorSystole1102 Cardiorespiratory Medicine and Haematologybusiness.industry030229 sport sciencesArticlesmedicine.diseaseTreatmentBlood pressureCardiovascular System & HematologyHypertensionBlood pressureScreeningDisease awarenessAlcohol intakeCardiology and Cardiovascular MedicinebusinessBody mass index
researchProduct

Dietary therapy and non-surgical periodontal treatment in obese patients with chronic periodontitis.

2018

Aim The effect of dietary weight loss intervention on periodontal therapy is unknown. Therefore, we aimed to evaluate whether weight loss improves the response of obese subjects to non-surgical periodontal treatment. Materials and methods This interventional study in obese patients was conducted at the University Hospital Dr. Peset (Valencia, Spain). Patients were divided into two groups with and without dietary therapy. All participants received non-surgical periodontal treatment. Periodontal, anthropometric and biochemical parameters were assessed at baseline and 12 weeks. Results A total of 78 patients were re-evaluated after intervention. All periodontal parameters improved in both grou…

medicine.medical_specialtyDiet therapy030209 endocrinology & metabolismSystemic inflammationGastroenterology03 medical and health sciences0302 clinical medicineWeight lossInternal medicinePeriodontal Attachment LossWeight LossMedicineHumansObesityPeriodontitisComplement component 3business.industry030206 dentistryAnthropometrymedicine.diseaseChronic periodontitisObesitySpainChronic PeriodontitisPeriodonticsmedicine.symptomPeriodontal IndexbusinessJournal of clinical periodontology
researchProduct

Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum

2019

Introduction: Pyoderma gangrenosum (PG) is a noninfectious, reactive inflammatory neutrophilic dermatosis that is commonly associated with autoimmune and neoplastic disorders. There are emerging diagnostic tools and treatment options for PG.Area covered: The diagnosis of PG should be seriously considered when managing ulcers to avoid unnecessary medical and surgical complications with prompt and suitable treatment. There are no standardized treatment guidelines for PG, and current therapy largely depends on the severity and progression of the disease. Systemic corticosteroids, immunosuppressant therapy, and biologic agents remain mainstay therapies. In this article, we present a literature …

medicine.medical_specialtyDiseaseDiagnostic toolsSeverity of Illness Index030226 pharmacology & pharmacySystemic therapyBiological Factors03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesmedicineHumansPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsIntensive care medicineClinical treatmentbusiness.industryGeneral MedicineGold standard (test)medicine.diseasePyoderma GangrenosumBiologic AgentsNeutrophilic dermatosis030220 oncology & carcinogenesisDisease ProgressionDermatologic AgentsbusinessImmunosuppressive AgentsPyoderma gangrenosumExpert Review of Clinical Pharmacology
researchProduct

Therapeutic dosages of oral or transdermal estradiol did not modify sCD40L levels in postmenopausal women.

2008

The CD40/CD40L system is considered a crucial modulator of the inflammatory process underlying the progression and complication of atheroma plaques. The soluble fraction of CD40L (sCD40L) is a reliable indicator of the CD40/CD40L system. Our purpose was to investigate whether a therapeutic dose of estradiol, by either the oral or the transdermal route, was associated with changes in circulating levels of sCD40L. Forty-seven women completed a 4-week course of treatment with either oral estradiol valerate (2 mg/day, 20 women) or transdermal estradiol (50 microg/day, 27 women). Serum levels of sCD40L were measured by conventional enzyme-linked immunosorbent assay. Oral, but not transdermal est…

medicine.medical_specialtyDoseEndocrinology Diabetes and MetabolismCD40 LigandAdministration OralEnzyme-Linked Immunosorbent AssayPharmacologyAdministration CutaneousFollicle-stimulating hormoneEndocrinologyTherapeutic indexInternal medicinemedicineHumansCD40 AntigensTriglyceridesTransdermalmedicine.diagnostic_testEstradiolbusiness.industryTransdermal routeEstradiol valerateObstetrics and Gynecologymedicine.diseaseAtherosclerosisMenopausePostmenopauseEndocrinologyCholesterolFemaleFollicle Stimulating HormoneLipid profilebusinessmedicine.drugGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
researchProduct